Immune Control is an emerging pharmaceutical company developing novel, orally available, small molecules for autoimmune/inflammatory diseases.

The company is commercializing the discovery that serotonin is a required growth factor for dividing lymphocytes. Certain serotonin antagonists eliminate activated or dividing T- or B-lymphocytes without disturbing resting lymphocytes. The ability to kill activated immune cells selectively has important implications for treating autoimmune/inflammatory diseases, hematologic cancers, and organ transplant rejection.

Immune Control is a first-mover and the leader in the emerging field of serotonin-based immunotherapeutics.

Our preclinical development program has yielded important insights into the design of orally available, potent, small molecules for autoimmune/inflammatory conditions. Immune Control is focused initially on two diseases: rheumatoid arthritis and asthma. Immune Control designs and develops novel compounds using in vitro and in vivo assays for receptor binding, efficacy, safety, and bioavailability. In 2008, the company plans to nominate two compounds as IND candidates for RA and asthma. In addition, we are conducting phase 1, proof-of-concept clinical trials in multiple myeloma and psoriasis, utilizing a currently approved serotonin antagonist.

Immune Control is a venture-backed, privately held company.

In June 2005, Immune Control closed an $11.3 million series A financing in which four venture capital firms participated: Domain Associates; BioAdvance Venture Fund/Quaker BioVentures; New Spring Capital; and, Anthem Capital Management. An additional $6 million was raised through existing investors in 2008.

Immune Control has an experienced management team.

Stephen Roth, Ph.D., president and CEO since 2003, was the founder, chief executive officer, and chairman of the board of Neose Technologies, Inc. Eric Sandquist, chief business officer, held senior leadership roles at Merck where he commercialized products in the United States and Europe. David Zopf, M.D., chief scientific officer, was the executive vice president and chief scientific officer of Neose. Nancy Jean Barnabei, chief financial officer, was formerly the vice president of finance, treasurer and chief financial officer for Locus Pharmaceuticals. Elliot Morales, vice president of operations, was previously a vice president of project management and analytical operations with Neose Technologies. Clayton Buck, Ph.D., director of R&D, was the acting director and CEO of the Wistar Institute.